Posted by admin on Aug 17th, 2022

Harvard Bioscience, Inc. (NASDAQ:HBIO – Get Rating) was the target of a significant decline in short interest in the month of July. As of July 31st, there was short interest totalling 315,400 shares, a decline of 13.8% from the July 15th total of 365,700 shares. Approximately 0.9% of the shares of the company are sold short. Based on an average daily volume of 292,800 shares, the short-interest ratio is presently 1.1 days.

Harvard Bioscience stock opened at $3.16 on Wednesday. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.42 and a quick ratio of 1.16. Harvard Bioscience has a 1-year low of $3.15 and a 1-year high of $8.48. The company has a market cap of $131.57 million, a PE ratio of -35.11 and a beta of 1.71. The stock’s 50 day moving average price is $3.66 and its 200 day moving average price is $4.71.

Harvard Bioscience (NASDAQ:HBIO – Get Rating) last posted its quarterly earnings results on Wednesday, August 3rd. The medical instruments supplier reported $0.02 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.01. Harvard Bioscience had a positive return on equity of 7.74% and a negative net margin of 3.03%. The firm had revenue of $29.21 million for the quarter, compared to the consensus estimate of $30.10 million. On average, sell-side analysts predict that Harvard Bioscience will post 0.05 EPS for the current fiscal year.

HBIO has been the topic of a number of recent research reports. TheStreet lowered Harvard Bioscience from a “c” rating to a “d+” rating in a report on Monday, May 23rd. KeyCorp decreased their price target on Harvard Bioscience from $10.00 to $7.00 and set an “overweight” rating on the stock in a research note on Friday, August 5th.

A number of institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in Harvard Bioscience by 12.8% during the first quarter. Vanguard Group Inc. now owns 1,924,517 shares of the medical instruments supplier’s stock worth $11,952,000 after purchasing an additional 218,832 shares in the last quarter. B. Riley Asset Management LLC boosted its position in Harvard Bioscience by 71.9% during the second quarter. B. Riley Asset Management LLC now owns 1,544,647 shares of the medical instruments supplier’s stock worth $5,561,000 after purchasing an additional 646,211 shares in the last quarter. AMH Equity Ltd boosted its position in Harvard Bioscience by 61.0% during the second quarter. AMH Equity Ltd now owns 1,250,000 shares of the medical instruments supplier’s stock worth $4,500,000 after purchasing an additional 473,747 shares in the last quarter. Renaissance Technologies LLC boosted its position in Harvard Bioscience by 5.6% during the second quarter. Renaissance Technologies LLC now owns 1,001,262 shares of the medical instruments supplier’s stock worth $3,605,000 after purchasing an additional 52,817 shares in the last quarter. Finally, Monarch Partners Asset Management LLC boosted its position in Harvard Bioscience by 62.5% during the second quarter. Monarch Partners Asset Management LLC now owns 801,259 shares of the medical instruments supplier’s stock worth $2,885,000 after purchasing an additional 308,057 shares in the last quarter. 72.75% of the stock is currently owned by hedge funds and other institutional investors.

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments.

Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.

Lightspeed Commerce Inc. (TSE:LSPD) Given Consensus Recommendation of “Moderate Buy” by Analysts

Umpqua Holdings Co. (NASDAQ:UMPQ) Receives Average Rating of “Hold” from Analysts